Takeda CEO Christophe Weber will now be able to boast about his elevation into the top 10 global pharma companies, if you base the count on revenue.
I cobbled together the latest set of figures for fiscal 2017 to show you where the Takeda/Shire operation fits in to the big picture. I’ll note that while J&J is way out front, it’s a healthcare/pharma conglomerate with a wide range of products in its portfolio. And I backed out crop sciences revenue from Bayer to make this more about biopharma.
Finally, I added Gilead as number 11 to provide some added context on Takeda/Shire.
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 30,500+ biopharma pros who read Endpoints News by email every day.Free Subscription